REG - Imaging Biometrics - IB Enters Agreement with MedImageMetric

Imaging BiometricsAnnouncement

16/09/2025 16:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250916:nRSP5731Za&default-theme=true

RNS Number : 5731Z  Imaging Biometrics Limited  16 September 2025

Imaging Biometrics Limited

(the "Company")

 

Imaging Biometrics Enters Agreement with MedImageMetric to Commercialize QSM
Technology

 

September 16, 2025 - Imaging Biometrics, LLC (IB), a leading provider of
advanced MRI analytics, is pleased to announce an agreement with
MedImageMetric, LLC (MIM) to commercialize its patented quantitative
susceptibility mapping (QSM) software, QSMetric™. QSMetric is available for
immediate sale through IB as an annual license subscription.

 

QSMetric, an FDA-cleared MRI technique, measures how tissue responds to
magnetic fields, revealing subtle biochemical changes often missed by
conventional imaging. It enables clinicians to quantify changes in magnetic
susceptibility, offering critical insights into iron deposition, microbleeds,
demyelination, calcification, and other markers of disease progression or
treatment response. The automated software has clinical applications across
neurodegenerative diseases, multiple sclerosis, neurological and psychiatric
disorders, cerebrovascular disease, traumatic brain injury, brain tumours, and
more-providing the sensitivity and specificity needed for confident diagnosis.

 

"This agreement brings together MIM's innovation and IB's commercialization
strength to accelerate access to a powerful, clinically validated imaging
solution," said Dr. Yi Wang, PhD, MIM's President. "The fact that QSMetric is
both FDA-cleared and patent-protected underscores its scientific rigor and
commercial readiness."

 

The collaboration also opens the door to joint development initiatives,
including:

·      Integration of QSMetric with IB's solutions to enhance neuro
characterization.

·      Expansion into multi-parametric imaging workflows for
neuro-oncology, neurodegeneration, and vascular disorders.

·      Co-development of AI-driven analytics and clinical decision
support tools leveraging QSMetric data.

 

A recent study published in Radiology demonstrated how QSM measures
iron-related pathology, supporting its role in managing neurodegenerative
diseases, particularly in predicting cognitive decline (Radiology, Sept 9,
2025 (https://doi.org/10.1148/radiol.250513) ). As demand for advanced imaging
in Alzheimer's care accelerates, QSMetric is well-placed to address a US
diagnostics market worth over $3.5 billion. With the rise of FDA-approved
anti-amyloid therapies, MRI-based monitoring for amyloid-related imaging
abnormalities (ARIA) has become a clinical and regulatory priority. QSMetric's
ability to detect and quantify microhemorrhages and iron accumulation
independent of imaging parameters (Radiology, Jan 1, 2012
(https://doi.org/10.1148/radiol.11110251) ) offers a robust quantitative
solution for ARIA-H surveillance-making it a valuable tool for memory clinics,
imaging networks, and trial sponsors navigating this rapidly expanding market.

"QSMetric is a perfect complement to our portfolio of advanced imaging
solutions," added Michael Schmainda, IB's CEO. "We're excited to bring this
technology to market and help clinicians unlock deeper insights into brain
pathology with greater precision and efficiency."

 

The Directors of the Company accept responsibility for the contents of this
announcement.

 

-ENDS-

 

For further information, please contact:

 

 

Imaging Biometric Limited

Trevor Brown/Dr Al Musella/Brett Skelly/Michael Schmainda

Tel: 020 7469 0930

 

Peterhouse Capital Limited (Broker)

Tel: 020 7220 9797

 

About Imaging Biometrics® LLC: IB is a wholly owned subsidiary of Imaging
Biometrics Limited, (LON: IBAI), and focuses on delivering quantitative
imaging platforms and therapeutics that transform how clinicians diagnose and
treat patients more efficiently and effectively. For more information about
Imaging Biometrics, visit the company's website at ww.imagingbiometrics.com.
Follow IB on X, @ImgBiometrics.

 

About MedImageMetric LLC: MIM is founded on technical and clinical research
development of imaging-based biomarkers. Based on rigorous biophysics and
computation, MIM has developed quantitative imaging biomarkers of tissue
function and metabolism for precision diagnosis and treatment.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRDZGMLDVVGKZM